All In Biotech

NDA 019830 · B Braun

Lidocaine Hydrochloride 0.8% and Dextrose 5% In Plastic Container

Lidocaine Hydrochloride · Injection

Last checked: Nov 20, 2026Latest source record: May 19, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1992

Apr 8, 1992

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,569

373 Phase 3, 196 recruiting

FAERS reports

177

176 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 19, 2026.

INDICATIONS AND USAGE Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 8, 1992 Original approval · Type 5 - New Formulation or New Manufacturer
3 products under this application
  • LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 800MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 200MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
  • LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER · LIDOCAINE HYDROCHLORIDE 400MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Lidocaine" as an intervention, any sponsor and status, largest first.

All 2,569 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective101
  • anaphylactic reaction7
  • dizziness5
  • seizure5
  • bradycardia4
  • headache4
  • hypertension4
  • hypotension4
  • loss of consciousness4
  • off label use4
  • tachycardia4
  • tinnitus4

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20142
20151
201610
20177
201831
20195
202022
202144
202212
202342
20241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 10, 2026

    Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20).

  • Current · updated Nov 10, 2026

    Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10).

  • Current · updated Nov 10, 2026

    Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,282 on PubMed

Sponsor: B Braun · Also marketed as Lidocaine Hydrochloride 0.2% and Dextrose 5% In Plastic Container, Lidocaine Hydrochloride 0.4% and Dextrose 5% In Plastic Container

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.